Crucell, DSM Biologics agreement gives MorphoSys access to PER.C6 for its antibody program

By Lisa Kerner

Charlotte, N.C., Aug. 17 - Crucell NV and technology partner DSM Biologics signed a second PER.C6 license agreement with MorphoSys AG.

The agreement allows MorphoSys to use the PER.C6 cell line in the development of material for its proprietary therapeutic antibody program, MOR103, for inflammatory diseases, according to a news release.

MorphoSys has signed a related biopharmaceutical manufacturing agreement with DSM Biologics to produce clinical grade material.

Financial details of the agreements were not disclosed.

"We are very pleased that respected antibody companies like MorphoSys are being convinced of the advantages of PER.C6 for antibody production," Crucell chief scientific officer Jaap Goudsmit said in a company news release.

"As we have seen with vaccines, PER.C6 is increasingly being accepted as the cell substrate for the production of antibodies."

Crucell is a biotechnology company based in Leiden, The Netherlands, focused on developing vaccines and antibodies that prevent and treat infectious diseases.

Parsippany, N.J.-based DSM Biologics, a business unit of DSM Pharmaceutical Products, provides manufacturing technology and services to the biopharmaceutical industry.

MorphoSys, based in Munich, Germany, develops and applies technologies for the production of synthetic antibodies for drug discovery and target characterization.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.